GlassScriptPhysician profile
John M Carwile
NPI 1487697686
$1,207.89
in general payments reported to CMS, 2019-2025
19 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $322.54 | 2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $182.40 | 2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $123.93 | 2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $96.86 | 2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.38 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $61.15 | 2025 | |
| Exact Sciences Corporation | $47.50 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.02 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $35.93 | 2025 | Gardasil 9, Capvaxive |
| Sumitomo Pharma America, INC. | $32.31 | 2025 | Gemtesa |
| Tolmar, INC. | $23.28 | 2025 | Jatenzo |
| Paratek Pharmaceuticals, INC. | $22.83 | 2025 | Nuzyra |
| Esperion Therapeutics, INC. | $22.55 | 2025 | Nexletol |
| Dexcom, INC. | $21.79 | 2025 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $18.87 | 2025 | Fanapt |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $18.13 | 2025 | NP Thyroid 60 |
| Currax Pharmaceuticals LLC | $16.55 | 2025 | Contrave |
| Amgen INC. | $15.20 | 2025 | Evenity |
| Dynavax Technologies Corporation | $13.67 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Carwile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.